Similar articles for PMID: 27165064

Year	Number of Results
2001	1
2007	3
2008	2
2009	1
2010	10
2011	8
2012	9
2013	9
2014	9
2015	8
2016	4
2017	1
2024	0

1

Effect of Target Therapy on the Content of Transcription and Growth Factors, Protein Kinase TOR, and Activity of Intracellular Proteases in Patients with Metastatic Renal Cell Carcinoma.

Spirina LV, Usynin EA, Kondakova IV, Yurmazov ZA, Slonimskaya EM. Spirina LV, et al. Bull Exp Biol Med. 2016 Apr;160(6):798-801. doi: 10.1007/s10517-016-3313-6. Epub 2016 May 10. Bull Exp Biol Med. 2016. PMID: 27165064 Clinical Trial.

2

Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.

Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME, Cerbone L, Sternberg CN, Hutson TE, Choueiri TK. Bellmunt J, et al. Clin Genitourin Cancer. 2014 Aug;12(4):262-9. doi: 10.1016/j.clgc.2014.03.002. Epub 2014 Mar 14. Clin Genitourin Cancer. 2014. PMID: 24795159

3

Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.

Albiges L, Fay AP, Xie W, Krajewski K, McDermott DF, Heng DY, Dariane C, DeVelasco G, Lester R, Escudier B, Choueiri TK. Albiges L, et al. Eur J Cancer. 2015 Nov;51(17):2580-6. doi: 10.1016/j.ejca.2015.08.017. Epub 2015 Sep 4. Eur J Cancer. 2015. PMID: 26346135

4

The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape.

Goebell PJ, Doehn C, Grüllich C, Grünwald V, Steiner T, Ehneß R, Welslau M. Goebell PJ, et al. Future Oncol. 2017 Jul;13(17):1463-1471. doi: 10.2217/fon-2017-0083. Epub 2017 May 19. Future Oncol. 2017. PMID: 28523933 Free article.

5

Future perspectives for mTOR inhibitors in renal cell cancer treatment.

Czarnecka AM, Kornakiewicz A, Lian F, Szczylik C. Czarnecka AM, et al. Future Oncol. 2015;11(5):801-17. doi: 10.2217/fon.14.303. Future Oncol. 2015. PMID: 25757683 Review.

6

Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Kaymakcalan MD, Xie W, Albiges L, North SA, Kollmannsberger CK, Smoragiewicz M, Kroeger N, Wells JC, Rha SY, Lee JL, McKay RR, Fay AP, De Velasco G, Heng DY, Choueiri TK. Kaymakcalan MD, et al. Cancer. 2016 Feb 1;122(3):411-9. doi: 10.1002/cncr.29773. Epub 2015 Nov 5. Cancer. 2016. PMID: 26540173 Free article.

7

Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.

Chen MC, Lee CF, Huang WH, Chou TC. Chen MC, et al. Biochem Pharmacol. 2013 May 1;85(9):1278-87. doi: 10.1016/j.bcp.2013.02.009. Epub 2013 Feb 14. Biochem Pharmacol. 2013. PMID: 23416116

8

Second-line therapy for refractory renal-cell carcinoma.

Zustovich F, Lombardi G, Nicoletto O, Pastorelli D. Zustovich F, et al. Crit Rev Oncol Hematol. 2012 Jul;83(1):112-22. doi: 10.1016/j.critrevonc.2011.08.008. Epub 2011 Sep 22. Crit Rev Oncol Hematol. 2012. PMID: 21944739 Review.

9

Evolving role of novel targeted agents in renal cell carcinoma.

Hutson TE, Figlin RA. Hutson TE, et al. Oncology (Williston Park). 2007 Sep;21(10):1175-80; discussion 1184, 1187, 1190. Oncology (Williston Park). 2007. PMID: 17926797 Free article. Review.

10

Combination therapy in metastatic renal cell cancer.

Ravaud A, Gross-Goupil M, Bellmunt J. Ravaud A, et al. Semin Oncol. 2013 Aug;40(4):472-81. doi: 10.1053/j.seminoncol.2013.05.010. Semin Oncol. 2013. PMID: 23972711 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

54 results

Results by year